Ascendiant Capital Maintains Buy on Cyclo Therapeutics, Lowers Price Target to $0.95
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on Cyclo Therapeutics but lowered the price target from $2.6 to $0.95, indicating a more cautious outlook.
August 26, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ascendiant Capital has maintained a Buy rating on Cyclo Therapeutics but lowered the price target from $2.6 to $0.95, suggesting a more cautious outlook on the stock's potential.
The lowering of the price target from $2.6 to $0.95 by Ascendiant Capital indicates a significant reduction in expected future performance, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100